Chicago Billionaire to Pay for $650 Million Soccer Stadium
By and Miranda Davis
Updated on
Save
Billionaire Joe Mansueto is using his fortune to build a new stadium for his Chicago soccer team.
The founder of Morningstar Inc. and owner of Chicago Fire FC said Tuesday he will personally fund a $650 million stadium to be built at a 62-acre development south of downtown called The 78. Set to open in 2028, the stadium will be able to accommodate 22,000 spectators.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
24 minutes ago
- News24
New Gauteng number plate finally unveiled
Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once. Start your FREE trial now Show Comments ()
Yahoo
34 minutes ago
- Yahoo
2 Recession-Proof Stocks to Buy and Hold
Even amid an uncertain economic environment, reliable companies can be found. Zoetis helps people care for pets, which many consider as honorary family members. HCA Healthcare offers services in high demand, regardless of economic conditions. 10 stocks we like better than Zoetis › President Trump's trade policies are sparking concerns about a potential recession. Though it's hard to predict an upcoming economic downturn, it's never a bad idea for investors to buy shares of companies that can perform relatively well even in bad times. These corporations often have robust underlying businesses built to deliver consistent results and superior returns over the long run. Here are two great examples for investors to consider: Zoetis (NYSE: ZTS) and HCA Healthcare (NYSE: HCA). Zoetis, a leading animal health company, has faced some challenges over the past year. The company's recent financial results weren't great, and it is dealing with increased competition for some of its growth drivers, including Apoquel, a medicine to treat allergic itch in dogs. However, as Zoetis points out, there is significant whitespace in this niche. It estimates that 13 million dogs are eligible for the medicine but aren't on any prescription, and another 7 million are undertreated. The company currently treats 12 million dogs with Apoquel and Cytopoint, a similar medicine. Although Zoetis markets products for livestock, poultry, and other animals, the company's work with pets, particularly cats and dogs, is one of the primary reasons it can survive a recession relatively unscathed. People view their pets as family members and are more than willing to pay a significant amount to ensure they are well cared for. The increased humanization of pets should also be a significant long-term growth driver for Zoetis, a trend that is particularly prevalent among younger generations, who are less likely to have children than older ones. It might be pushing it to say that pets are the new kids, but it's not too far from the truth for many pet owners. The rest of Zoetis' business grants it significant diversity. The animal health leader generally grows its revenue at rates faster than the industry average, something it has been able to do for a while, despite competition, through the continuous development of newer medicines. Two of its more recent important approvals, Solensia and Librela that treat osteoarthritis pain in cats and dogs, respectively, are becoming key growth drivers, too. So, despite being slightly in the red over the trailing-12-month period, Zoetis is well-equipped to handle a recession if one is coming, while delivering strong returns in the long run. Lastly, the stock is also an excellent pick for income seekers despite its unimpressive forward yield of 1.2%. Zoetis has increased its payouts by 502% in the past decade. Whether it's for dividends or growth, the healthcare specialist is a great option. HCA Healthcare's business remains in high demand even in recessions. The company is a leading hospital chain in the U.S., and even during economic downturns, people still require critical medical care. True, some procedures performed in the company's facilities are optional. Even for those that aren't, patients may sometimes postpone them when things get tough. So, there will be an impact on the company's results, but it should be fairly minimal. Over the past year, the company has faced another source of headwinds. Various natural disasters, including hurricanes, impacted its financial results in some areas, resulting in lower revenue than anticipated. Still, HCA Healthcare continues to deliver decent updates. In the first quarter, the company's revenue increased by a modest 5.7% year over year to $18.3 billion. Its earnings per share came in at $6.45, up 8.8% compared to the year-ago period. Despite this headwind, HCA Healthcare's long-term prospects are attractive. An aging population that will require more medical care should lead to increased spending on precisely the kinds of services it offers. HCA Healthcare has also deepened its relationships with physicians, patients, and third-party payers over time, partly through the adoption of more services. It would be challenging for any newcomer to seriously challenge HCA Healthcare, considering the ecosystem it has already built, which arguably grants it a network effect. Although there is competition, HCA Healthcare has generally increased its market share over the past decade. The stock should continue delivering superior returns long after the next recession hits, whenever that happens. Before you buy stock in Zoetis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Zoetis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Zoetis. The Motley Fool recommends HCA Healthcare. The Motley Fool has a disclosure policy. 2 Recession-Proof Stocks to Buy and Hold was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Charles Woodson Jr. talks new Michigan offer, legendary father's input
The New Year has been very good to Charles Woodson Jr. The Orlando (Fla.) Lake Nona High School defensive back has not only added his first scholarship offers, but has seen bigger and bigger programs jump in on the hot streak. Advertisement It hit another level on Wednesday night when Michigan came calling. The son of the former UM Heisman Trophy winner and NFL legend of the same name, Jr. also got to experience the news with his father simultaneously. "The secondary coach (LaMar Morgan) called my head coach a week ago," Woodson Jr. said. "Then the head coach (Sherrone Moore) told me and my dad to call him. "We're pretty excited about it. I mean it's where my dad went so it's pretty special and it's a huge program so it means a lot." The rising-junior prep recruit has of course been to Ann Arbor in the past, where he was able to experience the legacy he now has an opportunity to continue. Advertisement A return trip is likely to materialize soon. "I'll find a date," Woodson Jr. said. "I went when I was in eighth grade and the place is real cool." CLASS OF 2026 RANKINGS: Rivals250 | Team | Position | State CLASS OF 2027 RANKINGS: Rivals250 | Team | Position | State TRANSFER PORTAL: Full coverage | Player ranking | Team ranking | Transfer search | Transfer Tracker RIVALS CAMP SERIES: Rivals Five-Star heading back to Indy | Rivals Five-Star roster | Schedule/info With the run of new tenders in for Woodson Jr., including Florida State, Texas A&M, Ole Miss, Syracuse and several others since January, it is very early in the recruiting process for the versatile defensive back. Advertisement Still, the college and NFL legend may have nudged a bit when his alma mater came calling. "You know my dad is excited for real," he said. The Woodsons learned of the offer news amid a trek through the Lone Star State. A&M hosted the No. 11 nickel projection for a workout and he "loved the hospitality" earlier in the week. Texas also had them on campus this week. Outside of LNHS workouts, the emerging recruit said he is unsure of additional college visit plans at this time. As a sophomore in 2024, Woodson Jr. notched an interception and multiple pass breakups for the Lions. He also registered 53 total tackles and recovered a fumble, per MaxPreps.
